Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Anaemia Correction in Haemodialyzed Patients - Comparative Analysis of Two Erythropoietin Stimulating Agents Schedules (VAES)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00551603
Recruitment Status : Withdrawn (Logistic reasons, financial contrastraints)
First Posted : October 31, 2007
Last Update Posted : December 22, 2017
Sponsor:
Collaborators:
Dr Carol Davila Teaching Hospital of Nephrology
Romanian Renal Registry
Information provided by (Responsible Party):
Anemia Working Group Romania

Brief Summary:

Several recent reports support the efficacy of once every-other-week epoetinum administration in the maintenance phase of the anaemia treatment in predialysis, haemodialysis and in peritoneal dialysis CKD patients.

However, there are studies suggesting that in HD patients receiving SC short-acting ESA therapy, ESA efficacy decreases when the dosing is extended from thrice-weekly to once-weekly administration. When every-2-week administration of long-acting ESAs is extended to every 4 weeks, efficacy either remains stable or decreases incrementally. The GAIN trial (Gain effectiveness in Anemia treatment with NeoRecormon®) was designed to compare anemia management with epoetin beta, epoetin alpha or darbepoetin alpha in HD patients. An interim analysis of data from 1005 stable HD patients suggested that switching to epoetin beta from either epoetin alpha or darbepoetin alpha resulted in improved efficacy and a 20% dose reduction in SC epoetin beta.

The aim of the study is to compare two schedules of anaemia treatment in HD patients using two different erythropoietic stimulating agents (epoetinum beta vs darbepoetinum) with respect to the efficacy in anaemia correction and to the haemoglobin (Hb) level stability.

This is a multicenter (2 centers), prospective, open-label, parallel, controlled trial of therapy equivalence


Condition or disease Intervention/treatment Phase
Bio-Equivalency of 2 Treatment Schedules in HD Patients Drug: switch (epoetinum beta, darbepoetinum) Drug: continuation (darbepoetinum) Phase 4

Detailed Description:

Currently available ESAs include epoetin alfa, epoetin beta, and darbepoetin. Epoetin alfa and beta have been designed to resemble closely the endogenous molecule and have similar pharmacokinetics. They are considered "short-acting" in comparison to darbepoetin, a second-generation molecule with a prolonged half-life, which is considered "long-acting." European and American Best Practice Guidelines (EBPG) recommend preferential subcutaneous (SC) twice- to thrice-weekly epoetin administration. There is a great deal of evidence that once-weekly SC administration of epoetin beta to be equally efficient and well tolerated in HD patients, even in those requiring high weekly epoetin doses. Several recent reports support the efficacy of once every-other-week epoetinum administration in the maintenance phase of the anaemia treatment in predialysis, haemodialysis and in peritoneal dialysis CKD patients.

However, there are studies suggesting that in HD patients receiving SC short-acting ESA therapy, ESA efficacy decreases when the dosing is extended from thrice-weekly to once-weekly administration. When every-2-week administration of long-acting ESAs is extended to every 4 weeks, efficacy either remains stable or decreases incrementally . The GAIN trial (Gain effectiveness in Anemia treatment with NeoRecormon®) was designed to compare anemia management with epoetin beta, epoetin alpha or darbepoetin alpha in HD patients. An interim analysis of data from 1005 stable HD patients suggested that switching to epoetin beta from either epoetin alpha or darbepoetin alpha resulted in improved efficacy and a 20% dose reduction in SC epoetin beta.

The aim of the study is to compare two schedules of anaemia treatment in HD patients using two different erythropoietic stimulating agents (epoetinum beta vs darbepoetinum) with respect to the efficacy in anaemia correction and to the haemoglobin (Hb) level stability.

The trial is designed according to the Guidelines for studies testing the equivalence of different treatment regimens , and will be conducted with the provisions of the Declaration of Helsinki and Tokio as amended in Venice (1983).

This is a multicenter (2 centers), prospective, open-label, parallel, controlled trial of therapy equivalence.

The total observation period is of 80 weeks:

  • The baseline phase (pre-therapeutic intervention) - 12 weeks;
  • The first study phase of therapeutical intervention - 48 weeks: each the two groups of patients will receive anaemia treatment according to the Romanian Best Practice Guidelines either with epoetinum beta or with darbepoetinum;
  • The second study phase of therapeutical intervention - 24 weeks: the patients from the epoetinum beta group will be switched to darbepoetinum. The anaemia treatment will continue according to the Romanian Best Practice Guidelines, using the recommended conversion factor of 200 (Romanian Best Practice Guidelines, NKF-DOQI 2006, Revised EBPG).

    300 haemodialyzed patients will be enrolled.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Anaemia Correction in Haemodialyzed Patients - Comparative Analysis of Two Erythropoietin Stimulating Agents Schedules
Actual Study Start Date : July 2006
Actual Primary Completion Date : December 2008
Actual Study Completion Date : March 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia

Arm Intervention/treatment
Experimental: 1
Group Epo will receive anaemia treatment according to the Romanian Best Practice Guidelines recommendation, with once-weekly SC epoetinum beta during the first phase, then will be switched to receive SC once-fortnightly darbepoetinum. Anaemia treatment schedule will continue according to the Romanian Best Practice Guidelines recommendations, with the same dose. A conversion factor of 1:200 will be used.
Drug: switch (epoetinum beta, darbepoetinum)
switching from epoetinum beta once weekly to once-fortnightly darbepoetinum
Other Name: Group Epo

Active Comparator: 2
Subjects in the Darbepo Group will receive anaemia treatment according to the Romanian Best Practice Guidelines recommendation, with once-fortnightly or once-monthly darbepoetin SC administration, continuing their previous schedule and will continue their previous schedule of anaemia treatment during the second phase of the study
Drug: continuation (darbepoetinum)
continuation of the previous darbepoetinum administration schedule
Other Name: Darbepo Group




Primary Outcome Measures :
  1. - hemoglobin level during the study and - monthly ESA dose per dry body weight during the study [ Time Frame: 80 weeks of the study ]

Secondary Outcome Measures :
  1. - percentage of patients maintaining target Hb without increase in ESA dose - difference between the average Hb during second study phase period versus the first one and versus baseline phase [ Time Frame: during the study ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adult age (≥18 years)
  • at least 6 months HD
  • efficient HD (urea-equilibrated Kt/V >1.2, Daugirdas II equation)
  • haemoglobin (Hb) levels above 10g/dL
  • treatment with an ESA for at least 12 weeks prior to enrollment
  • serum ferritin level 100-800 ng/mL
  • transferrin saturation 20-50%.

Exclusion Criteria:

  • hepatic diseases (as defined by abnormal ALT and AST levels) or association of psychical disorders or other disturbances making the enrollment unacceptable, as judged by the physician
  • acute infection or HIV infection
  • severe hyperparathyroidism (iPTH >800 ng/mL)
  • active bleeding
  • > 5% variation in dry body weight in the last 6 months
  • previously diagnosed folic acid and/or vitamin B12 deficiency
  • neoplastic diseases
  • other known causes of anaemia
  • known hypersensibility to one of the administered drugs
  • epilepsy
  • pregnancy or lactation
  • anti-viral treatment during the month before the inclusion
  • immunosuppressive treatment or use of other medication known to influence erythropoiesis during the month preceding the enrollment
  • need for blood transfusions within 12 weeks prior to enrollment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00551603


Locations
Layout table for location information
Romania
"Dr Carol Davila" Fresenius NephroCare Dialysis Centre
Bucharest, Romania, 0107231
IHS Dialysis Centre "Sf Ioan Nou" Clinical Hospital
Bucharest, Romania
Sponsors and Collaborators
Anemia Working Group Romania
Dr Carol Davila Teaching Hospital of Nephrology
Romanian Renal Registry
Investigators
Layout table for investigator information
Study Director: Liliana Garneata, MD, PhD Anemia Working Group
Study Chair: Gabriel Mircescu, Professor Anemia Working Group
Principal Investigator: Carmen Barbulescu, MD "Dr Carol Davila" NephroCare Dialysis Centre
Study Director: Alexandru Ciocalteu, Professor "IHS" Dialysis Centre "Sf Ioan Nou" Clinical Hospital
Principal Investigator: Daniela Ciortea, MD, PhD IHS Dialysis Centre, "Sf Ioan Nou" Clinical Hospital
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Anemia Working Group Romania
ClinicalTrials.gov Identifier: NCT00551603    
Other Study ID Numbers: AWG_03_07
1246/ANM
First Posted: October 31, 2007    Key Record Dates
Last Update Posted: December 22, 2017
Last Verified: December 2017
Keywords provided by Anemia Working Group Romania:
epoetinum beta once-weekly
darbepoetinum once-fortnightly
anemia correction
hemoglobin stability
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia
Hematologic Diseases